BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 21810561)

  • 1. The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract.
    Matuschek C; Bölke E; Peiper M; Knoefel WT; Budach W; Erhardt A; Scherer A; Gerber PA; Buhren BA; Gattermann N; Baldus SE; Rusnak E; Shukla V; Orth K
    Eur J Med Res; 2011 Jun; 16(6):265-74. PubMed ID: 21810561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (Neo)-adjuvant chemo(-radio) therapy for adenocarcinomas of the gastroesophageal junction and the stomach in the West.
    Wilke H; Lordick F; Meyer HJ; Stahl M
    Dig Surg; 2013; 30(2):112-8. PubMed ID: 23867587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 4. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
    Fernandez E; Cacheux W; Frossard JL; Koessler T; Abou M; Moniez M; Huber O; Puppa G; Roth A
    Dig Liver Dis; 2017 May; 49(5):552-556. PubMed ID: 28179095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esophagogastric junction and gastric adenocarcinoma: neoadjuvant and adjuvant therapy, and future directions.
    Sandler S
    Oncology (Williston Park); 2014 Jun; 28(6):505-12. PubMed ID: 25134325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint].
    Ott K; Lordick F
    Chirurg; 2009 Nov; 80(11):1028-34. PubMed ID: 19756431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
    Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualized surgical strategies for cancer of the esophagogastric junction.
    Stein HJ; Feith M; Siewert JR
    Ann Chir Gynaecol; 2000; 89(3):191-8. PubMed ID: 11079787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
    Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
    Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversies in the treatment of local and locally advanced gastric and esophageal cancers.
    Cohen DJ; Leichman L
    J Clin Oncol; 2015 Jun; 33(16):1754-9. PubMed ID: 25918302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment approaches to esophagogastric junction tumors.
    Kurokawa Y; Sasako M; Doki Y
    Dig Surg; 2013; 30(2):169-73. PubMed ID: 23867594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Siewert III Adenocarcinoma: Still Searching for the Right Treatment Combination.
    Tang A; Sohal D; McNamara M; Murthy SC; Raja S
    Surg Oncol Clin N Am; 2020 Oct; 29(4):647-653. PubMed ID: 32883464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer?
    Moorcraft SY; Smyth EC; Cunningham D
    Gastric Cancer; 2015 Jan; 18(1):1-10. PubMed ID: 24638977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neoadjuvant therapy of adenocarcinomas of the upper gastrointestinal tract. Status of radiotherapy].
    Semrau R; Vallböhmer D; Hölscher AH; Müller RP
    Chirurg; 2009 Nov; 80(11):1035-41. PubMed ID: 19820906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
    Borg D; Larsson AH; Hedner C; Nodin B; Johnsson A; Jirström K
    J Transl Med; 2018 Oct; 16(1):290. PubMed ID: 30355278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
    Rivera F; Izquierdo-Manuel M; García-Alfonso P; Martínez de Castro E; Gallego J; Limón ML; Alsina M; López L; Galán M; Falcó E; Manzano JL; González E; Muñoz-Unceta N; López C; Aranda E; Fernández E; Jorge M; Jiménez-Fonseca P
    Eur J Cancer; 2021 Mar; 145():158-167. PubMed ID: 33485079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
    Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.
    Vošmik M; Laco J; Sirák I; Dvořák J; Lochman P; Hodek M; Malá P; Rejchrt S; Repák R; Leško M; Ferko A; Ryška A; Melichar B; Petera J
    Pathol Oncol Res; 2018 Apr; 24(2):373-383. PubMed ID: 28550507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.